BeOne Medicines AG (6160.HK) stock price, financials & research

Regular session · HKT · Market data may be delayed.

Company profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Industry: Biotechnology
Sector: Healthcare
Headquarters: CH
CEO: John V. Oyler
Listed since: Aug 8, 2018
Employees: 12,000

Market position

Day range

Current HK$221.8

HK$219.6HK$227.2

52-week range

Current HK$221.8

HK$153HK$235.6

Open: HK$224
Previous close: HK$228
Volume: 1.51M; 0.3× average
Average volume: 4.95M; Average daily volume
Market cap: 295.23B HKD
Beta: 0.5; Market reference 1
50-day average: HK$189.64; +16.96% above average
200-day average: HK$190.3; +16.55% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 29.16B USD
P/E (TTM): 62.2×
P/B (TTM): 7.93×
P/S (TTM): 6.15×
EV / EBITDA: 49.45×
Earnings yield: 0.88%
Free cash flow yield: 2.89%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 87.82%
Operating margin: 15.06%
Net margin: 10.70%
Return on equity: 6.59%
Return on assets: 3.49%
Return on invested capital: 4.76%

Financial health

Debt / equity: 0.22×
Current ratio: 3.41×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin

Income trends

Revenue

5.35B USD+40.44%

Operating income

447.8M USD+1.02B USD

Net income

287.36M USD+932.14M USD

Metric (USD)	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	5.35B USD	3.81B USD	2.46B USD	1.42B USD	1.18B USD
Cost of goods sold	787.72M USD	594.09M USD	379.92M USD	1.93B USD	1.62B USD
Gross profit	4.56B USD	3.22B USD	2.08B USD	−511.06M USD	−447.86M USD
Research and development	2.08B USD	1.95B USD	1.78B USD	1.64B USD	1.46B USD
Selling, general, and administrative	2.04B USD	1.83B USD	1.5B USD	1.28B USD	990.12M USD
Operating expenses	4.12B USD	3.78B USD	3.29B USD	1.28B USD	990.87M USD
Interest income	70.61M USD	47.84M USD	74.01M USD	52.48M USD	15.76M USD
Interest expense	58.32M USD	—	—	—	—
Depreciation and amortization	141.9M USD	171.76M USD	87.68M USD	66.28M USD	46.46M USD
Operating income	447.8M USD	−568.2M USD	−1.21B USD	−1.79B USD	−1.44B USD
Net income	287.36M USD	−644.79M USD	−881.71M USD	−2B USD	−1.46B USD